Jazz Pharmaceuticals(JAZZ)
Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
Mock data
Subscribe for the real data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name | Drug Name | Approved | Patent Expires | Indication |
|---|---|---|---|---|
| Defitelio | Defibrotide | 2016-03-30 | 2032 | |
| Erwinaze | Asparaginase erwinia chrysanthemi | 2011-11-18 | — | |
| Fazaclo | Clozapine | 2004-02-10 | 2028 | |
| Luvox | Fluvoxamine | 2008-02-28 | ||
| Rylaze | Asparaginase erwinia chrysanthemi (recombinant) | 2021-06-30 | ||
| Vyxeos (previously vyxeos) | Cytarabine, Daunorubicin | 2018-08-23 | 2025-2032 | |
| Xyrem | Oxybate | 2002-07-17 | 2024-2042 | |
| Xywav | Magnesium oxybate, Oxybate, Potassium oxybate | 2020-07-21 | 2024-2042 | |
| Zepzelca | Lurbinectedin | 2020-06-15 | 2029 | |
| Epidyolex | Cannabidiol | 2019-09-19 | 2035-2041 | |
| Enrylaze | Crisantaspase | 2023-09-15 | ||
| Epidiolex | Cannabidiol | 2018-09-28 | 2035-2041 |
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Indication |
|---|---|---|---|---|---|
1
2
3
4
5
6
7
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use